Object. Gamma Knife surgery (GKS) has been shown to be effective for treating many patients with brain metastasis. Some brain metastases demonstrate significant peritumoral edema; radiation may induce cerebral edema or worsening preexisting edema. This study was conducted to evaluate the imaging and neurobehavioral outcomes in patients with preexisting peritumoral edema who then undergo GKS.
B efore the advent of GKS, fractionated radiotherapy and resection were the mainstays of treatment for brain metastases. Gamma Knife surgery plays a substantial role in brain metastasis tumor control and affords many patients improved survival and QOL. Radiosurgery can be used to treat multiple metastases during the same procedure and permits treatment of deep deposits considered surgical inaccessible. 18, 23, 24 Some brain metastases demonstrate significant peritumoral edema on MR imaging at the time a patient presents for GKS. 25 Several hypotheses of peritumoral edema have been postulated such as secretion of vascular endothelial growth factor, inflammation cytokines, and destruction of blood-brain barrier by the tumor itself. 4, 5, 8, 13, 22 The pathophysiology of peritumoral brain edema can reflect neuron loss or demyelination and may be reversible or irreversible. 9, 21 Tumor control is an important outcome mea-sure in the treatment of metastatic brain tumors, but the response of peritumoral edema may have profound implications in terms of motor weakness, epilepsy, visual field defect and aphasia and the QOL for patients. 18, 23, 24 From the point of view of QOL, the control or resolution of peritumoral edema may be as important as local tumor control.
Gamma Knife surgery is a complex process in which one must balance the dose necessary to treat an intracranial lesion with the risks of inducing dose-dependent toxicities such as radiation edema or necrosis from the treatment. Approximately 90% of metastatic tumors are responsive to GKS, but there is a risk of radiation edema or necrosis related to the radiosurgical dose-volume histogram. 6, 18, 23, 24 Shuto and associates 25 reported that the tumor response in metastatic brain lesions is positively related to resolution of peritumoral edema. However, the improvement in QOL, preexisting treatment such as WBRT or radiosurgery, and a measurement tool in evaluating brain edema were not well addressed. 25 In this study, we investigated the effect of GKS on a single metastatic tumor with peritumoral significant (> 20 cm 
Methods

Patient Population and Edema Assessment
Based on the usual radiosurgical dose-volume histogram, the upper limit of tumor volume in metastatic brain tumor treated by GKS usually is < 20 cm ; 2) in the case of multiple metastatic lesions, only the targeted lesion that harbored peritumoral brain edema was > 20 cm 3 ; other lesions had to be smaller and with no visible edema on T2-weighted MR imaging. All tumors evaluated were located outside the brainstem. The T2-weighted imaging and FLAIR volumes were computed by segmenting the respective T2-weighted imaging and FLAIR areas around a brain metastasis, computing the area per slice, and then integrating the slice areas over the encompassing region of the MR imaging.
Three days before and after GKS, the patient received intravenous dexamethasone (10 mg/day). Then, the patients were maintained on oral dexamethasone (0.5 mg) 3-4 times per day for 2 weeks. Most patients were then tapered off steroids unless they were found to be steroid dependent secondary to edema-related neurological symptoms. The duration and dosage of dexamethasone were recorded. All patients received MR imaging with pulse sequences of T1-weighted, T2-weighted, and FLAIR images with or intravenous Gd contrast injection with the interval of 3 months until the patient died; these imaging sequences are part of our routine protocol in the follow-up in metastatic brain tumors. The neurological outcome and BCM-20 life questionnaire were obtained every 2-3 months. The BCM-20 was administered by the patient's treating neurosurgeon or a clinical assistant on his team.
The median age of the patient population was 59 years (range 28-36 years). Thirty-five patients were men and 28 were women. Clinical presentation included focal neurological deficits in 33; neurological deficits were absent in 30. The median KPS score was 70 (range 50-90). The mean BCM-20 was 45.5 ± 6.1. The histological diagnosis included adenocarcinoma of lung (43 patients), squamous cell carcinoma of lung (5 patients), small cell carcinoma (1 patient), breast adenocarcinoma (7 patients), 7 renal cell carcinoma (3 patients), hepatocellular carcinoma (2 patients), transitional cell carcinoma of bladder (1 patient), and endometrial carcinoma of uterus (1 patient). Before GKS, 8 patients had undergone a craniotomy followed by radiotherapy, 21 patients had WBRT, and 1 had XKnife (Integra LifeSciences) radiosurgery followed by WBRT.
Tumor Parameters
The brain metastases were widely distributed throughout the brain tissues as follows: 11 tumors in the frontal lobes, 28 in the parietal lobes, 7 in the occipital lobes, 4 in the temporal lobes, 3 in the basal ganglion, and 10 in the cerebellum. The mean tumor volume was 5.2 ± 4.6 cm 3 with a corresponding FLAIR volume of 62.1 ± 38.8 cm 
Treatment Parameters
Gamma Knife surgery was performed using the Leksell Gamma Knife unit (model C, Elekta Instruments). The mean maximum dose was 35 Gy (range 24-45 Gy), and the mean margin dose was 17.4 Gy (range 12-22 Gy). Thirty-three patients without a history of prior cranial irradiation received a mean prescription dose of 18.2 Gy (range 13-22 Gy). Thirty patients with a history of radiation therapy either with WBRT or XKnife radiosurgery received a mean margin dose of 16.4 Gy (range 12-20 Gy).
Follow-Up Imaging
Periodic follow-up neuroimaging was performed using MR imaging; studies were obtained every 2-3 months following the treatment and continued until the end of the study or the death of the patient. The MR imaging slice thickness was 2-3 mm for T1-weighted images or time of flight with and without Gd contrast administration. The MR imaging slice thickness was 3-5 mm for T2-weighted images and FLAIR without contrast administration. The tumor volumes were determined on MR imaging images using a picture archiving and communications system (that is, PACS) and compared with those obtained during GKS planning. We graded the tumor response according to the following volume changes at follow-up: > 20% volume enlargement as tumor increase, > 20% volume de-crease as tumor shrinkage, and stable tumor as a volume change < 20%. 17 Postradiosurgical imaging studies were available for 48 of 63 brain metastases.
Clinical Follow-Up
The patients underwent regular neurological followup examinations at 1-to 3-month intervals. Late-onset toxicities including delayed symptomatic edema, necrosis, and hemorrhage were assessed by the physical examination and correlated with imaging findings. The neurological outcome and BCM-20 questionnaire were obtained every 2-3 months. 19 The causes of death were grouped as due to brain metastasis progression, extracranial disease progression, or unknown.
Statistical Analysis
The Kaplan-Meier survival analysis and Cox proportional hazard mode for risk factors were performed. Logistic regression analysis was used to analyze the associated factors affecting the tumor response and the resolution of peritumoral brain edema. The statistical analysis was performed with the aid of the software package SPSS 10.1.
Results
Clinical Outcome
The median survival of the patients was 11 months (range 3-44 months). At last follow-up, 38 patients were dead and 25 patients were alive. The univariate and multivariate analyses of the median survival are shown in Table 1 . For the univariate analysis, longer survival was observed for patients < 65 years old, nonlung cancer metastatic tumors, KPS score ≥ 70, no neurological deficits at presentation, a BCM-20 decrease by 6, and better tumor and edema response following GKS. For the multivariate analysis, patients < 65 years old with a KPS score ≥ 70 and a BCM-20 decrease by 6 demonstrated significantly longer survival.
The BCM-20 score before GKS were negatively correlated to the tumor volume, T2-weighted imaging/ FLAIR volume, and the value of KPS as depicted in Table  2 . The patients with and without neurological deficits had mean BCM-20 scores of 48.27 ± 6.31 and 42.53 ± 4.27, respectively (p = 0.0002). The BCM-20 score after radiosurgery with and without local neurological deficits was 42.55 ± 11.35 and 34.23 ± 8.72, respectively (p = 0.0034). The BCM-20 values for those patients with decreasing, Table 3 . A BCM-20 decrease following GKS was not correlated to T1-weighted imaging volume, T2-weighted imaging volume, and FLAIR volume, but it did relate to KPS score and margin dose. This indicates that the improvement of the BCM-20 score correlated to the tumor response and resolution of edema, but the improvement in BCM-20 did not directly relate to the tumor or edema volume before GKS.
Imaging Outcome
Forty-eight patients had at least 1 set of follow-up images. The mean duration of imaging follow-up was 12 ± 7.3 months. The T1-weighted imaging volume alternation compared with FLAIR is shown in Table 4 . Thirty-seven (77.1%) of 48 patients exhibited decreased tumor volume as well as decreased T2-weighted imaging and FLAIR volume at the 3-month follow-up (Fig. 1) . The mean duration of a patient on a regimen of dexamethasone was 4.5 ± 2.1 weeks. One patient was tapered from the dexamethasone at 3 weeks, but remained on prednisolone treatment due to respiratory-associated problems. Five patients had tumor recurrence at a mean follow-up of 9 ± 2.1 months, and 8 patients developed new metastatic lesions at a mean follow-up of 10 ± 3.9 months. Among those with recurrent tumor, the increased tumor volume was consistently paralleled with an increase in the FLAIR signal (Fig.  1E-H) . One (2.1%) of 48 patients initially exhibited an increased tumor size and FLAIR volume at the followup of 3 months but subsequently showed a decrease in enhancement and FLAIR signal at the 6-month followup (Fig. 2) . This was presumed to be radiation-induced changes. Eight (16.7%) of 48 patients showed increased or stable size of tumor volume and the corresponding increase or stable size in T2-weighted imaging and FLAIR volume. Among these 8 patients, 2 patients underwent a craniotomy and tumor resection (at 3 and 5 months after GKS), and one underwent a second GKS procedure followed by radiotherapy (6 months after GKS). One (2.1%) of 48 patients demonstrated an increase in tumor volume without increased T2-weighted imaging and FLAIR volumes (Fig. 3) . Another patient (2.1%) showed a tumor volume decrease without a decrease of the T2-weighted imaging and FLAIR volumes (Fig. 4) . The mean duration of dexamethasone maintenance in those without resolution of peritumoral edema was 26.5 ± 7.9 weeks.
The factors associated with tumor response (decrease, increase/stable) following GKS are detailed in Table 5 . There were no statistically significant differences in tumor response related to initial tumor volume, FLAIR volume, overall number of intracranial tumors, tumor pathology, and previous irradiation. However, higher margin dose (> 18 Gy) and maximum dose (> 30 Gy) portended better tumor control (p = 0.005 and p < 0.001, respectively). A similar trend was also observed in the resolution of peritumoral brain edema (Table 6 ). Higher margin dose (> 18 Gy) and maximum dose (> 30 Gy) resulted in better resolution of peritumoral edema (p = 0.006 and p = 0.004, respectively). Nevertheless, prior brain irradiation correlated with worsened peritumoral edema (p = 0.023), and a longer maintenance of steroid was observed in tumors persistent with peritumoral edema on MR imaging (p < 0.001).
Discussion
The present study found that preexisting peritumoral brain edema did not influence the tumor response after GKS. However, the resolution of brain edema and responsiveness of the tumor to treatment were related to improvements in QOL. The BCM-20 is a reliable method QOL measurement; it was related to KPS score, edema volume, and tumor volume. Longer survival in patients with metastatic tumor was related to KPS score ≥ 70, age < 65 years, and improved BCM-20 score (that is, BCM-20 score decrease of > 6 points). In metastatic brain tumors demonstrating peritumoral brain edema (> 20 cm 3 ), GKS not only achieved excellent tumor response but also did not appear to aggravate preexisting edema. 25 Thus, in performing GKS in patients with metastatic tumors, significant initial peritumoral edema should not be considered as an absolute contraindication to GKS.
The causes of peritumoral brain edema included secretory and mechanic factors. The secretory factors consisted of endothelial growth factor, aquaporin, arachidonic acid, and phospholipids degeneration of cell membrane. The mechanic factors included fenestration of vessel by the tumor and occlusion of venous drainage system 4,5,7,8,13,22 Suppression of secretory factors and restoration of mechanic factors is essential for edema control. The tumor pathology also influences the resolution of brain edema. For example, excellent resolution of peritumoral brain edema by GKS was observed in lung and breast cancer. However, poor regression of the edema was obtained in those with renal cell carcinoma metastases. This phenomenon may be explained in part by higher secretion factor release from the renal cell carcinoma metastases. To overcome inherently radiation-resistant metastases, a higher GKS dose is recommended. 25 Furthermore, the tumor volume and blood supply is crucial for the development of peritumoral brain edema. 12 In this study, we found the volume of edema was related to size of tumor. Thus, it was no surprise that the resolution of edema was associated with a decrease in tumor size. In some tumors, a decreased volume of enhancement was observed, but the volume of edema reciprocally increased in size. The pathology of such resected tumors invariably revealed that active tumor was still present in the lesion even though decreased enhancement was observed. Based on the strong correlation in the tumor response, resolution of peritumoral edema by MR imaging and pathological findings, the resolution of brain edema appears more associated with secreted factors from the metastatic tumors instead of the mechanic factors such as the size of the tumor.
A T2-weighted MR imaging sequence is a commonly used method for estimating brain edema. 12, 25 The margin of brain edema on T2-weighted imaging contiguous to the cerebrospinal fluid system (near the sulci and ventricles) was difficult to delineate. However, FLAIR sequence imaging had greater power to distinguish the edema from the cerebrospinal fluid system, and any subtle change in demyelination correlated significantly with changes on T2-weighted imaging. 9, 27 In this study, we observed that the volume of peritumoral brain edema based on T2-weighted imaging approached the edematous volume noted on FLAIR sequences. Furthermore, the marginal segmentation for brain edema was more easily conducted using the FLAIR-based sequence. As such for brain metastasis patients undergoing GKS, FLAIR sequences appear to be a reliable measurement of brain edema volume at the moment of diagnosis as well as during the follow-up period.
The control of the peritumoral brain edema by GKS appears related to the pathology of the primary tumor and dose used during radiosurgery. The metastatic tumor con- fig. 1 . Magnetic resonance images obtained in this 78-year-old man who presented with left limb weakness that had persisted for 2 weeks. A stereotactic biopsy revealed non-small cell lung cancer. Axial FLAIR sequence obtained at the time of GKS, revealing peritumoral brain edema in the left parietal region (A). Axial T1-weighted image with contrast demonstrating a heterogeneously enhancing partially cystic lesion in the left parietal lobe (B). The patient underwent GKS with treatment volume of 6.1 ml and margin dose of 18 Gy to the 50% isodose curve. Six months after GKS, the FLAIR (C) and T1-weighted imaging (D) volumes were decreased. Eighteen months after GKS, the volume in FLAIR (E) and T1-weighted imaging (F) showed a paralleling increase. G and H: Twenty-one months after GKS, the volume in FLAIR (G) and T1-weighted imaging with contrast administration (H) shows a further increase. The patient is still alive; at last follow-up, he has a KPS score of 90 and BMC-20 of 29. V = tumor volume.
trol rate in lung, breast, and renal metastatic brain tumors were 82, 83, and 63.8%, respectively. The tumor control rate was better in those that received a higher margin dose (> 25 Gy). 25 However, an increase in the T2-weighted imaging volume on postradiation therapy imaging was related the 12-Gy volume, and the incidence of postradiosurgical-worsened edema was as high as 57% when the 12-Gy volume was > 15 cm 3 . 11 Thus, when selecting dose, one must consider the benefits of a higher dose in terms of growth control with the risk of worsening peritumoral edema. In this study, we found that 79% of brain metastases with edema had improvement following GKS. The resolution of edema was related to a decreased tumor size, which is compatible with a previous report. 25 In patients who presented with recurrence of metastatic disease to the brain, GKS achieved a tumor control rate as high as 92.4%, which was comparable to those undergoing GKS as a primary treatment. 18 In this study, we found that GKS as a salvage treatment for recurrent or residual tumor still achieved a favorable rate of tumor control.
The antiedematous effect of steroids in alleviating peritumoral edema is well established. The exact mechanism remained unclear, but tightening of leaky bloodbrain barrier and promotion of absorption of edema into the glial cells have been proposed. 1, 15, [25] [26] [27] Shuto and colleagues 25 reported that steroid use did not enhance prolonged peritumoral edema control in patients with metastatic brain tumors. Sinha and colleagues 26 reported that dexamethasone decreased the value of diffusion tensor MR imaging. Such changes in diffusion tensor imaging were compatible with a normalization of peritumoral brain water homeostasis but without significant alternation in T2-weighted imaging. 26 In this study, steroid administration started shortly before GKS and was tapered fig. 2 . Three years previously, renal cell carcinoma had been diagnosed in this 60-year-old man. The patient presented with a 1-month history of left limb weakness, and a brain metastasis was diagnosed. He underwent GKS with a treatment volume of 1.8 ml and a margin dose of 18 Gy to the 65% isodose line. Axial T2-weighted (A) and FLAIR (B) images showing severe brain edema. Axial T1-weighted image with contrast revealing a homogeneous enhancing metastatic deposit (C). D-F: Three months later, the T2-weighted and FLAIR volume showed an initial increase. Six months later, the T2-weighted (G) and FLAIR (H) imaging volumes demonstrated paralleling decreases along with that of the T1-weighted image with contrast (I). The patient died of aspiration pneumonia 8 months after GKS.
shortly thereafter in accordance with the patient's symptoms. We found that the interval of steroid use was shorter in patients who demonstrated tumor reduction following radiosurgery. It seemed that the steroid use played a significant role in temporarily alleviating edema. However, based on the statistical analysis, the duration of steroid use was closely related to the tumor and peritumoral edematous response. One drawback is that this study lacked a control group without steroid administration. Hence, the contribution of steroids in alleviating peritumoral edema was not fully determined in this study. The steroid administration contributed to part of the effect in alleviating peritumoral edema, but the favorable tumor response by GKS is a crucial factor in providing lasting relief of peritumoral brain edema.
Preservation of neurocognitive function and QOL are now viewed as critical goals in the treatment of those with metastatic brain tumors. 2, 14, 19, 20 Brain tumor-specific health-related QOL were assessed by a questionnaire (BCM-20) developed by Osoba et al. 16 It contained 5 multi-item scales (future uncertainty, visual disorder, motor dysfunction, communication deficits, and emotional distress) and 7 single items asking about headache, seizure, drowsiness, hair loss, itching, weakness in the legs, and difficulty in bladder control. The modified BCM-20 was used for the evaluation of neurobehavioral status and health-related QOL studies of patients with glioma or metastatic brain tumor; the improvement in neurological function and imaging outcome were related to an accompanying significant decrease of the BCM-20 value. 3, 10 In this study, we found that the status and alteration of BCM-20 were related to the presence/development of neurological deficits. White matter change denoted by abnormal signal change in T2-weighted and FLAIR in MR imaging have been linked to changes in cognitive function. 9 The resolution of peritumoral brain edema and decreased tumor size was correlated with a decrease in the BCM-20. Thus, BCM-20 appears to be a valuable method to predict the neurological outcome as well as the QOL of a patient with brain metastasis who is to undergo radiosurgery. fig. 4 . This 59-year-old woman with endometrial carcinoma underwent a total hysterectomy and bilateral oophorectomy followed by chemotherapy 3 years previously. Multiple brain metastases occurred 6 months prior to presentation for radiosurgery. She had undergone WBRT of 30 Gy in 10 fractions. Left leg weakness was observed 2 months after radiation therapy. A and B: T2 and FLAIR sequence MR imaging revealing severe brain edema. C: T1 with contrast MR imaging showed multiple cystic lesions. She underwent GKS with a treatment volume of 18 ml and margin dose of 14 Gy in 40% isodose curve. D and E: Six months after GKS, T2 and FLAIR volumes were not altered. F: The T1 with contrast volume was reduced. The patient remains alive with a KPS score of 80 and BCM-20 of 35.
Conclusions
Gamma Knife surgery can be effective in treating a brain metastasis even in the setting of significant (> 20 cm 3 ) peritumoral edema. Resolution of brain edema and a well-controlled (stable or decreased) brain tumor portended a better QOL for these patients. Longer survival was observed in patients with KPS scores ≥ 70, a decrease in BCM-20 index > 6, and age < 65 years.
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